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Hepatitis B virus (HBV) infection is common in indivi-
duals infected with human immunodeficiency virus, and
coinfection is associated with higher rates of HBV repli-
cation and more rapid liver disease progression than
HBV monoinfection. This study evaluates the prevalence
and virological profiles of hepatitis B infection in a
cohort of long term survivors, with multiple antiretro-
viral treatments.
164 HIV-infected subjects (median age: 24 years) on
combined antiretroviral therapy (cART) (median dura-
tion: 13 years), were evaluated for serologic markers of
HBV infection (HBsAg, total anti-HBc and anti-HBsAg
antibodies). Markers of HBV infectivity (HBeAg and
HBV DNA) were evaluated in all HBsAg carriers; HBV
genotype and lamivudine resistance mutations were ana-
lyzed in the cases with HBV DNA >103 IU/mL.
65.9% of the patients (108/164) had markers of past or
present HBV infection (antiHBc positives), out of which
51.8% (56/108) were chronic HBV carriers and 30.5% had
resolved HBV infection. All subjects were equally exposed
to HBV infection, irrespective of their current immune
status. Out of 21 patients with isolated anti-HBc antibo-
dies, only 4 had detectable HBV DNA, presumably having
occult hepatitis B. HBV chronic carriage rate was not
influenced by the immune status. Overall, only 17.8% of
the chronic carriers had active HBV replication; severely
immune-depressed patients tend to maintain active viral
replication more frequently than those with moderate or
absent immunosuppression. The majority of the coin-
fected individuals (68.3%) showed no sign of liver fibrosis
(APRI score <0.5), only 3% had severe fibrosis (APRI
score >1.5); HBV DNA was directly correlated with APRI
score. HBV genotype A was present in all but one of the
tested patients. 98.8% of the coinfected subjects have been
treated with a cART regimen that includes a drug dually
active against HIV and HBV (in 98% of the cases lamivu-
dine (3TC), for a mean time of 6.9 years and in 29.7% of
the cases the current dually active drug was tenofovir).
3TC-resistance mutations were present in only 4 coin-
fected subjects.
We found a strikingly low percentage of long term HIV/
HBV coinfected patients from our group with active liver
disease. A high prevalence of asymptomatic HBV chronic
carriage was associated with a good immune status, sug-
gesting that dually active antiretrovirals have an important
role in delaying progression of liver disease in HIV/HBV
coinfected patients.
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